» Articles » PMID: 29795134

Pharmacological Actions of Miltirone in the Modulation of Platelet Function

Overview
Specialty Pharmacology
Date 2018 May 26
PMID 29795134
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Salvia miltiorrhiza Bunge contains various active constituents, some of which have been developed as commercially available medicine. Moreover, some other ingredients in Salvia miltiorrhiza play roles in anti-platelet activity. The aim of the present study was to investigate the effects and the underlying mechanism of miltirone, a lipophilic compound of Salvia miltiorrhiza Bunge. The ability of miltirone to modulate platelet function was investigated by a variety of in vitro and in vivo experiments. Platelet aggregation and dense granule secretion induced by various agonists were measured with platelet aggregometer. Clot retraction and spreading were imaged by digital camera and fluorescence microscope. Ferric chloride-induced carotid injury model and pulmonary thromboembolism model were used to check miltirone antithrombotic effect in vivo. To elucidate the mechanisms of anti-platelet activity of miltirone, flow cytometry and western blotting were performed. Miltirone (2, 4, 8 µM) was shown to suppress platelet aggregation, dense granule, and α granule secretion in a dose-dependent manner. Meanwhile, miltirone inhibited the clot retraction and spreading of washed platelets. It reduced the phosphorylation of PLCγ2, PKC, Akt, GSK3β and ERK1/2 in the downstream signal pathway of collagen receptor. It also reduced the phosphorylation of Src and FAK in the integrin αIIbβ3-mediated "outside-in" signaling, while it did not suppress the phosphorylation of β3. In addition, miltirone prolonged the occlusion time and reduced collagen/epinephrine-induced pulmonary thrombi. Miltirone suppresses platelet "inside-out" and "outside-in" signaling by affecting PLCγ/PKC/ERK1/2, PI3K/Akt, and Src/FAK signaling. Therefore, miltirone might represent a potential anti-platelet candidate for the prevention of thrombotic disorders.

Citing Articles

Nicotine's impact on platelet function: insights into hemostasis mechanisms.

Wu X, Liu Y, Zou C, He F, Guo F, Liu S Front Pharmacol. 2025; 15:1512142.

PMID: 39902074 PMC: 11788582. DOI: 10.3389/fphar.2024.1512142.


Natural Occurring Terpene Cyclic Anhydrides: Biosynthetic Origin and Biological Activities.

Molina Inzunza D, Martin Gonzalez J, Segura Navarro M, Barrero A, Quilez Del Moral J Biomolecules. 2024; 14(8).

PMID: 39199343 PMC: 11352521. DOI: 10.3390/biom14080955.


Tentative exploration of pharmacodynamic substances: Pharmacological effects, chemical compositions, and multi-components pharmacokinetic characteristics of ESZWD in CHF-HKYd rats.

Hong L, Zhao Y, Chen W, Yang C, Li G, Wang H Front Cardiovasc Med. 2022; 9:913661.

PMID: 36186966 PMC: 9515952. DOI: 10.3389/fcvm.2022.913661.


Molecular Mechanism of Bunge in Treating Cerebral Infarction.

Ye X, Liu J, Yuan X, Yang S, Huang Y, Chen Y Evid Based Complement Alternat Med. 2022; 2022:5992394.

PMID: 35392650 PMC: 8983215. DOI: 10.1155/2022/5992394.


Fruitflow inhibits platelet function by suppressing Akt/GSK3β, Syk/PLCγ2 and p38 MAPK phosphorylation in collagen-stimulated platelets.

Chen H, Zhang S, Wang H, Bao L, Wu W, Qi R BMC Complement Med Ther. 2022; 22(1):75.

PMID: 35300669 PMC: 8932123. DOI: 10.1186/s12906-022-03558-5.


References
1.
Phillips D, Prasad K . Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling. Thromb Haemost. 2001; 86(1):246-58. View

2.
Valli G, Giardina E . Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002; 39(7):1083-95. DOI: 10.1016/s0735-1097(02)01749-7. View

3.
Calderwood D . Integrin activation. J Cell Sci. 2004; 117(Pt 5):657-66. DOI: 10.1242/jcs.01014. View

4.
Kuliopulos A, Mohanlal R, Covic L . Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost. 2004; 92(6):1387-93. DOI: 10.1160/TH04-03-0187. View

5.
Watson S, Auger J, McCarty O, Pearce A . GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost. 2005; 3(8):1752-62. DOI: 10.1111/j.1538-7836.2005.01429.x. View